Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results
Advancing investigation of [212Pb]VMT01 as a monotherapy and in combination with the anti-PD-1 antibody, nivolumab, in patients with previously treated […]